Category Archives: Stem Cell Medicine


Researchers discover new class of stem cells

Researchers have identified a new class of lab-engineered stem cells -- cells capable of transforming into nearly all forms of tissue -- and have dubbed them F-class cells because they cluster together in "fuzzy-looking" colonies.

The discovery, which was described in a series of five papers published Wednesday in the journals Nature and Nature Communications, sheds new light on the process of cell reprogramming and may point the way to more efficient methods of creating stem cells, researchers say.

Due to their extraordinary shape-shifting abilities, so-called pluripotent cells have enormous value to medical researchers. They allow scientists to study the effects of drugs and disease on human cells when experiments on actual people would be impossible, and they have given rise to the field of regenerative medicine, which seeks to restore lost or damaged organs and tissues.

The F-class cells were created using genetically engineered mouse cells, and may not occur naturally outside the lab, according to senior author Andras Nagy, a stem cell researcher at Torontos Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital.

However, the find suggests that there may be other classes of pluripotent cells -- or a spectrum of reprogrammed cells -- yet to be discovered, authors say.

We think that if we have time, and money and hands to do it, we might find additional novel cell lines, Nagy said.

Until now, stem cells have been either obtained from embryos or produced in the lab through a painstaking process called induced pluripotency, whereby a virus is used to alter an adult cells genetic information and return the cell to a pliable, embryonic state.

That process, which was pioneered by Dr. Shinya Yamanaka and recognized with the Nobel Prize in Physiology or Medicine in 2012, is extremely inefficient, yielding embryonic-stem-cell-like cells just 1% of the time.

Nagy and his colleagues, a consortium of international researchers called Project Grandiose, began their research by looking more closely at the castoffs of that process, or those cells that did not closely match the description of embryonic stem cells.

We looked at it in an unbiased way, Nagy said. Instead of ignoring or discarding those cells that dont look like embryonic stem cells, we thought we might find more than just one alternative cell type.

Read the original:
Researchers discover new class of stem cells

Stem cell discovery could lead to hair loss treatments

CALGARY New research from the University of Calgary may hold the key to restoring hair growth.

The findings, published in the scientific journal Developmental Cell this week, identify the existence of a skin stem cell in adult hair follicles that may one day be targeted to stimulate new hair growth after injury, burns, disease or aging.

The discovery is being called an important a step towards new hair loss treatments.

We hope that we can ultimately stimulate these cells with drugs to replenish or rejuvenate the cells that are responsible for inducing hair growth, says assistant professor in stem cell biology at the Faculty of Veterinary Medicine Jeff Biernaskie, PhD.

Hair follicles undergo a constant cycle of regeneration and degeneration, and Biernaskie wanted to identify the stem cells that oversee that cycle.

Biernaskies team discovered that a small number of dermal sheath cells could self-renew, and gave rise to hundreds of new cells in each hair follicle.

He says the discovery gives researchers a greater understanding of how hair follicles regenerate and it opens the door to creating therapies targeting stem cells to restore hair growth.

However, it could be a decade before such therapies are developed.

Biernaskies research holds hope for animals as well as humans.

Animals suffer skin diseases and injuries similar to people, and he says anything that improves the understanding of stem cells in healing and regeneration in people is also applicable to healing in animals.

See the rest here:
Stem cell discovery could lead to hair loss treatments

New UQ platform aids stem cell research

Researchers at The University of Queensland are part of a global team that has identified a new type of artificial stem cell.

UQ Associate Professor Christine Wells (right) said Project Grandiose had revealed it could track new ways to reprogram a normal adult cell, such as skin cells, into cells similar to those found in an early embryo.

The development is expected to help researchers explore ways to arrive at new cell types in the laboratory, with important implications for regenerative medicine and stem cell science.

Associate Professor Wells, who leads the Stemformatics stem cell research support unit at UQs Australian Institute for Bioengineering and Nanotechnology, said the project involved a consortium of 50 researchers from Canada, Australia, Korea, the USA and the Netherlands

We all come from just one cell the fertilised egg and this cell contains within its DNA a series of instruction manuals to make all of the many different types of cells that make up our body, AIBN Associate Professor Wells said.

These very early stage cells can now be made in the lab by reversing this process of development.

Our research reveals the new instructions imposed on a cell when this developmental process is reversed.

Project Grandiose is a large-scale research effort to understand what happens inside a cell as it reverts to an artificial stem cell.

The role of the Stemformatics.org group was to help the researchers have access to the vast information and data they generated from the project, Associate Professor Wells said.

Our online data platform is designed to let non-specialists view the genes involved and the many ways they are regulated during cell formation.

Continued here:
New UQ platform aids stem cell research

Stem Cells from Adult Nose Tissue Used to Cure Parkinsons Disease in Rats

Durham, NC (PRWEB) December 05, 2014

Scientists have for the first time used adult human stem cells to cure rats with Parkinsons disease, a neurodegenerative illness that currently has no cure. The study, published in the current issue of STEM CELLS Translational Medicine, details how a team of researchers working in Germany at the University of Bielefeld (UB) and Dresden University of Technology were able to produce mature neurons using inferior turbinate stem cells (ITSCs).

ITSCs are stem cells taken from tissue that would generally be discarded after an adult patient undergoes sinus surgery.

The team then tested how the ITSCs would behave when transplanted into a group of rats with Parkinsons disease. Prior to transplantation, the animals showed severe motor and behavioral deficiencies. However, 12 weeks after receiving the ITSCs, the cells had migrated into the animals brains and functional ability was not only fully restored, but significant behavioral recovery was witnessed, too. In another positive sign, no tumors were found in any of the animals after the transplantations, something that also has been a concern in stem cell therapy.

Due to their easy accessibility and the resulting possibility of an autologous transplantation approach, ITSCs represent a promising cell source for regenerative medicine, said UBs Barbara Kaltschmidt, Ph.D., who led the study along with Alexander Storch, M.D., and Christiana Ossig, M.D., both of Dresden University. The lack of ethical concerns associated with human embryonic stem cells is a plus, too.

In contrast to fighting the symptoms of Parkinsons disease with medications and devices, this research is focused on restoring the dopamine-producing brain cells that are lost during the disease, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "These cells are easy to access and isolate from nasal tissue, even in older patients, which adds to their attraction as a potential therapeutic tool.

###

The full article, Intrastriatal transplantation of adult human neural crest-derived stem cells improves functional outcome in Parkinsonian rats can be accessed at http://www.StemCellsTM.com.

Continue reading here:
Stem Cells from Adult Nose Tissue Used to Cure Parkinsons Disease in Rats

Global Stem Cells Group Hands-on Training Course in Barcelona Heading to Additional Euro Cities in 2015

MIAMI (PRWEB) December 04, 2014

After a successful first run in Spain last month, Global Stem Cells Group, has announced the decision to take the biotech companys hands-on stem cell training course to additional European cities in 2015. GSCG subsidiary Stem Cell Training, Inc. and Dr. J. Victor Garcia conducted the Adipose Derived Harvesting, Isolation and Re-integration Training Course for medical professionals in Barcelona Nov. 22-23, 2014.

The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctors office by teaching effective, in-office regenerative medicine techniques.

Global Stem Cells Group will release a schedule of cities and dates for future training classes in upcoming weeks.

For more information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group: Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

Read the original here:
Global Stem Cells Group Hands-on Training Course in Barcelona Heading to Additional Euro Cities in 2015

The Adult Stem Cell Technology Center, LLCs New Report on Asymmetric Character of Stem Cell Chromosomes Advances …

Boston, MA (PRWEB) December 04, 2014

In a new report published in the online journal Cell Death and Disease, the Adult Stem Cell Technology Center, LLC (ASCTC) continues to demonstrate its special expertise in uncovering unknown properties that are unique to adult tissue stem cells. In particular, the new study continues to build the companys portfolio of technologies that make previously invisible adult stem cells not only identifiable, but also countable.

The studies were performed with mouse hair follicle stem cells. Because of the universal nature of adult tissue stem cell properties, the new findings are predicted to apply to stem cells in a wide range of human tissues as well.

For the past half century since the experimental demonstration of their existence, it has not been possible to identify adult tissue stem cells exclusive of other related cell types. Consequently, counting them has been impossible, too. Established stem cell therapies like bone marrow transplantation are suboptimal because of this limitation; and the current worldwide flood of thousands of clinical trials of tissue stem cell transplantation therapies has the same problem. Without being able to count potentially curative adult tissue stem cells, there is no way to optimize and standardize successful treatments.

The new report presents a discovery made during studies employing one of the ASCTCs recently defined biomarkers for detecting tissue stem cells. The new biomarker is a member of a family of cell factors called histones that package the cellular DNA into chromosomes. One of the less abundant members of this family is called H2A.Z. In 2011, the ASCTC discovered that H2A.Z is only accessible on the set of chromosomes that segregates to the stem cell sister when a stem divides to produce a non-stem sister cell. The non-stem sister differentiates to replenish lost mature tissue cells. Before a stem cell divides in this manner, the stem cell chromosomes and the non-stem cell chromosomes are distinct because of this difference in their H2A.Z access. This unique feature, called H2A.Z asymmetry, is a highly specific biomarker for identifying adult tissue stem cells.

Because detection of H2A.Z asymmetry does not disrupt other features of stem and non-stem chromosomes, it can be used as a specific landmark to discover other molecular differences between chromosomes destined for the stem cell sister and chromosomes destined for the non-stem sister. The new report describes how two well-known gene regulation modifications of an abundant histone family member, H3, also display asymmetry between stem cell chromosomes and differentiating cell chromosomes.

The newly discovered asymmetric chromosomal patterning of gene regulation modifications in adult tissue stem cells may reveal a long sought mechanism to explain how stem cell fate is maintained in mammalian tissues. This new insight into the function of tissue stem cells addresses a fundamental question in the field of stem cell biology research. ASCTC Director James L. Sherley anticipates that the new report will give stem cell scientists and bioengineers a new lead idea and new research tools for extending knowledge on the molecular workings of adult tissue stem cells. Such advances in knowledge are greatly needed currently to improve the scientific foundation for the increasing number of regenerative medicine clinical trials.

******************************************************************************************** The Adult Stem Cell Technology Center, LLC is a Massachusetts life sciences company. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the three main technical problems production, quantification, and monitoring that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells. Currently, ASCTC is employing its technological advantages to pursue commercialization of facile methods for monitoring adult tissue stem cell number and function.

Visit link:
The Adult Stem Cell Technology Center, LLCs New Report on Asymmetric Character of Stem Cell Chromosomes Advances ...

Not all induced pluripotent stem cells are made equal: McMaster researchers

PUBLIC RELEASE DATE:

3-Dec-2014

Contact: Veronica McGuire vmcguir@mcmaster.ca 90-552-591-402-2169 McMaster University @mcmasteru

Hamilton, ON (Dec. 3, 2014) - Scientists at McMaster University have discovered that human stem cells made from adult donor cells "remember" where they came from and that's what they prefer to become again.

This means the type of cell obtained from an individual patient to make pluripotent stem cells, determines what can be best done with them. For example, to repair the lung of a patient with lung disease, it is best to start off with a lung cell to make the therapeutic stem cells to treat the disease, or a breast cell for the regeneration of tissue for breast cancer patients.

Pluripotency is the ability stem cells have to turn into any one of the 226 cell types that make up the human body.The work challenges the previously accepted thought that any pluripotent human stem cell could be used to similarly to generate the same amount of mature tissue cells.

This finding, published today in the prestigious science journal Nature Communications, will be used to further drug development at McMaster, and potentially improve transplants using human stem cell sources.

The study was led by Mick Bhatia, director of the McMaster Stem Cell and Cancer Research Institute. He holds the Canada Research Chair in Human Stem Cell Biology and he is a professor in the Department of Biochemistry and Biomedical Sciences of the Michael G. DeGroote School of Medicine.

"It's like the stem cell we make wants to become a doctor like its grandpa or an artist like its great-grandma," said Bhatia.

"We've shown that human induced pluripotent stem cells, called iPSCs, have a memory that is engraved at the molecular/genetic level of the cell type used to make them, which increases their ability to differentiate to the parent tissue type after being put in various stem cell states.

Read more from the original source:
Not all induced pluripotent stem cells are made equal: McMaster researchers

Not All Induced Pluripotent Stem Cells Are Made Equal

Released: 1-Dec-2014 1:00 PM EST Embargo expired: 3-Dec-2014 5:00 AM EST Source Newsroom: McMaster University Contact Information

Available for logged-in reporters only

Newswise Hamilton, ON (Dec. 3, 2014) Scientists at McMaster University have discovered that human stem cells made from adult donor cells remember where they came from and thats what they prefer to become again.

This means the type of cell obtained from an individual patient to make pluripotent stem cells, determines what can be best done with them. For example, to repair the lung of a patient with lung disease, it is best to start off with a lung cell to make the therapeutic stem cells to treat the disease, or a breast cell for the regeneration of tissue for breast cancer patients.

Pluripotency is the ability stem cells have to turn into any one of the 226 cell types that make up the human body.The work challenges the previously accepted thought that any pluripotent human stem cell could be used to similarly to generate the same amount of mature tissue cells.

This finding, published today in the prestigious science journal Nature Communications, will be used to further drug development at McMaster, and potentially improve transplants using human stem cell sources.

The study was led by Mick Bhatia, director of the McMaster Stem Cell and Cancer Research Institute. He holds the Canada Research Chair in Human Stem Cell Biology and he is a professor in the Department of Biochemistry and Biomedical Sciences of the Michael G. DeGroote School of Medicine.

Its like the stem cell we make wants to become a doctor like its grandpa or an artist like its great-grandma, said Bhatia.

Weve shown that human induced pluripotent stem cells, called iPSCs, have a memory that is engraved at the molecular/genetic level of the cell type used to make them, which increases their ability to differentiate to the parent tissue type after being put in various stem cell states.

So, not all human iPSCs are made equal, Bhatia added. Moving forward, this means that iPSC generation from a specific tissue requiring regeneration is a better approach for future cellular therapies. Besides being faster and more cost-efficient in the development of stem cell therapy treatments, this provides a new opportunity for use of iPSCs in disease modeling and personalized drug discovery that was not appreciated before.

Continued here:
Not All Induced Pluripotent Stem Cells Are Made Equal

Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

PUBLIC RELEASE DATE:

26-Nov-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine

Induced pluripotent stem cells made from patients with a form of blistering skin disease can be genetically corrected and used to grow back healthy skin cells in laboratory dishes, researchers at the Stanford University School of Medicine have found. They've termed the new technique "therapeutic reprogramming."

The skin cells formed normal human skin when grafted onto the backs of laboratory mice, they said.

The findings represent a major advance in the battle against the disease, epidermolysis bullosa, in which the top layer of skin, called the epidermis, sloughs off with the slightest friction, leaving open wounds that are difficult to heal. Severely stricken children who survive into their late teens or early 20s often die from invasive squamous cell carcinoma, a skin cancer that can arise during repeated cycles of skin wounding and healing.

"Epidermolysis bullosa is a truly horrible, debilitating skin disease in which the top layer of skin is not properly anchored to the underlying layers," said Anthony Oro, MD, PhD, professor of dermatology. "When they are born, the trauma of birth rips away their skin, and they continue to suffer severe skin wounds that require constant bandaging and medical attention throughout their lives."

Stanford has one of the largest epidermolysis bullosa clinics in the world, with an extremely active and engaged population of patients and their families eager to help researchers. The Stanford Department of Dermatology has been working to find new treatments for the disease for over 20 years. The latest advance, in which researchers replaced the mutated, disease-causing gene in the donor-made induced pluripotent stem cells with a healthy version, was funded by an $11.7 million grant from the California Institute for Regenerative Medicine.

New avenue of treatment

"This treatment approach represents an entirely new paradigm for this disease," Oro said. "Normally, treatment has been confined to surgical approaches to repair damaged skin, or medical approaches to prevent and repair damage. But by replacing the faulty gene with a correct version in stem cells, and then converting those corrected stem cells to keratinocytes, we have the possibility of achieving a permanent fix -- replacing damaged areas with healthy, perfectly matched skin grafts."

Visit link:
Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

American Spine Launches Plasma Rich Platelet Therapy and Stem Cell Therapy Treatments

Frederick, Maryland (PRWEB) November 25, 2014

American Spine is a practice on the cutting edge, committed to providing the latest, most effective, and innovative treatments for its patients. As part of this philosophy, American Spine joins the excitement surrounding Regenerative Medicine, a modern and progressive field of orthopedics and sports medicine. Regenerative Medicine involves the application of biological therapy treatments that enhance the body's ability to heal itself.

Dr. Sandeep Sherlekar, M.D., an owner and physician at American Spine, comments: "PRP and Stem Cell Treatments are revolutionary regeneration options for now and the future."

The major benefit of PRP and Stem Cell Therapy Treatments is the use of the patient's own whole blood, bone marrow stem cells and adipose stem cells, thus eliminating the risk of rejection or infection from other donors. These treatments are increasing in popularity as an alternative to other more invasive techniques in treating ailments such as: Muscle Tears, Meniscus and ACL Injuries, Tennis and Golf Elbow, Patellofemoral Pain Syndrome, various types of Tendonitis, Plantar Fasciitis, Spine Disease with either Degenerative Disks or Annular Tearing, Osteoarthritis in the joints and many more. They are used as a way to speed healing after other methods of treatment or to aid in the healing of resistant, long lasting injuries.

The blood and/or stem cells are harvested from the patient and are then prepared using state-of-the-art technologies. The preparation of PRP allows for a platelet sample that is 5 times more concentrated with platelets than normal blood. Similarly, the preparation of the patient's stem cells produces a much higher concentration of stem cells, both of which are essential in the healing process. The PRP and/or stem cells are then injected back into the patient's injured or degenerated tissues under guided imaging. The potential complications of such treatments are similar to those associated with regular joint injections.

American Spine stringently follows the FDA guidelines for the clinical use of blood and stem cells. We do not expand, reproduce or grow anything within a culture.

If you are interested in learning more about these treatments as a method to your own healing process or that of your patients, please visit the following link: http://www.americanspinemd.com/blog/platelet-rich-plasma-prp-and-autologous-stem-cell-treatment or call our offices to request additional information about these revolutionary therapies. We are offering a free consultation for new patients who are considering these treatments. The individual patient's treatment protocol will be formulated and discussed during the consultation.

At American Spine, our multidisciplinary team of physicians treat each patient's individual needs. Using the latest techniques and state-of-the-art equipment to diagnose pain, our practitioners determine a plan to meet each patient's unique diagnosis. We have assembled the very best team of healthcare professionals who can most effectively help our patients with a compassionate and personalized approach. We have 10 Maryland locations and one location in Gettysburg, PA to service your individual needs.

Contact Information: American Spine 1050 Key Parkway, Suite 104, Frederick, MD 21702 ph: 240-629-3939 http://www.americanspinemd.com

###

See more here:
American Spine Launches Plasma Rich Platelet Therapy and Stem Cell Therapy Treatments